Drug Trial Radar · NCT04950127
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
238
Actual
Start
Aug 27, 2021
Primary completion
Oct 28, 2024
Study completion Dec 20, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
Conditions
- Pruritus
Interventions
LinerixibatDrug
Participants will receive linerixibat.
PlaceboDrug
Participants will receive placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Mean Change From Baseline in Monthly Itch Scores Over 24 Weeks Using Numerical Rating Scale (NRS)Time frame: Baseline and up to Week 24
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Erlangen, Germany
GSK Investigational Site
Münster, Germany
GSK Investigational Site
Cambridge, United Kingdom
GSK Investigational Site
Durham, United Kingdom
GSK Investigational Site
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.